Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial

ORIGINAL ARTICLE
Sefri Noventi Sofia, Bahrudin, Ignatius Riwanto, Anindita Soetadji, Hardhono, Muhammad Thifan Satyagraha

 
For citation: Sofia SN, Bahrudin, Riwanto I, Soetadji A, Hardhono, Satyagraha MT. Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial. International Journal of Biomedicine. 2025;15(2):273-278. doi:10.21103/Article15(2)_OA1
 
Originally published June 5, 2025
 

Abstract: 

Background: Acyanotic congenital heart disease (ACHD) with left-to-right shunting frequently presents with pulmonary hypertension (PH), especially in developing countries where treatment options are often limited and costly. Cilostazol, a phosphodiesterase-3 inhibitor, has vasodilatory and inotropic effects, but its impact on pulmonary vascular resistance (PVR) and pulmonary blood flow (Qp) in this condition remains unclear. The aim of this study was to evaluate the effect of adding cilostazol to standard beraprost therapy on PVR and Qp in patients with ACHD complicated by PH.
Methods and Results: This double-blind randomized controlled trial involved 40 subjects with ACHD and PH. Participants were assigned to receive either cilostazol plus beraprost or placebo plus beraprost for three months.
In the cilostazol+beraprost group, PVR significantly decreased from 11.1±11.8 to 10.1±10.9 Wood units (P=0.001), while Qp showed no significant change (11.5±6.49 vs. 13.3±9.34; P=0.128). The beraprost-only group showed a smaller decrease in PVR (11.1±13.2 vs. 10.6±12.8; P=0 .006), but a significant increase in Qp (15.9±17.6 vs. 17.1±18.8; P=0.007). The E/e ratio for right ventricle diastolic function improved significantly only in the combination group.
Conclusion: Adding cilostazol to beraprost reduces pulmonary artery pressure without significantly increasing pulmonary blood flow, possibly by improving right ventricular diastolic function in ACHD patients with PH.

Keywords: 
congenital heart disease • pulmonary hypertension • phosphodiesterase inhibitor • prostacyclin analogue
References: 
  1. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J. 2017 Jul 7;38(26):2034-2041. doi: 10.1093/eurheartj/ehx034. PMID: 28369399.
  2. Lee SY, Kim SJ, Son JS, Kim SH, Lee CH. Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease. Korean Circ J. 2015 Sep;45(5):408-15. doi: 10.4070/kcj.2015.45.5.408. Epub 2015 May 8. PMID: 26413109; PMCID: PMC4580700.
  3. Xi SB, Wang SS, Qian MY, Xie YM, Li JJ, Zhang ZW. Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease. Chin Med J (Engl). 2019 Apr 5;132(7):811-818. doi: 10.1097/CM9.0000000000000145. PMID: 30789367; PMCID: PMC6595852.
  4. Zarambaitė E, Ramantauskaitė G, Krivickienė A, Siudikas A, Miliauskas S, Ereminienė E. The Treatment Strategy for the Atrial Septal Defect in the Presence of Severe Pulmonary Hypertension. Medicina (Kaunas). 2022 Jul 2;58(7):892. doi: 10.3390/medicina58070892. PMID: 35888611; PMCID: PMC9323680.
  5. Chen W, Chen J, Peng M, Luo J, Qiu H, Chen Y, Li J. Long-term survival of shunt closure in atrial septal defects with pulmonary arterial hypertension. Int J Cardiol. 2025 Jun 1;428:133094. doi: 10.1016/j.ijcard.2025.133094. Epub 2025 Feb 28. PMID: 40024302.
  6. Murala JSK, Karl TR, Pezzella AT. Pediatric Cardiac Surgery in Low-and Middle-Income Countries: Present Status and Need for a Paradigm Shift. Front Pediatr. 2019 Jun 13;7:214. doi: 10.3389/fped.2019.00214. PMID: 31263686; PMCID: PMC6584790.
  7. Dinarti LK, Anggrahini DW, Lilyasari O, Siswanto BB, Hartopo AB. Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines. Glob Heart. 2021 Apr 20;16(1):23. doi: 10.5334/gh.944. PMID: 34040936; PMCID: PMC8064285.
  8. Liang X, Wang Y, Zhao C, Cao Y. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. PLoS One. 2022 Nov 1;17(11):e0275392. doi: 10.1371/journal.pone.0275392. PMID: 36318524; PMCID: PMC9624404.
  9. Aiad N, du Fay de Lavallaz J, Zhang MJ, Chaikijurajai T, Ye B, Nijjar PS, Lahiri JA, Martin CM, Alexy T, Meyer M. Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial. ESC Heart Fail. 2025 Apr;12(2):1437-1446. doi: 10.1002/ehf2.15162. Epub 2024 Nov 17. PMID: 39552153; PMCID: PMC11911562.
  10. Avitabile CM, Vorhies EE, Ivy DD. Drug Treatment of Pulmonary Hypertension in Children. Paediatr Drugs. 2020 Apr;22(2):123-147. doi: 10.1007/s40272-019-00374-2. PMID: 31960361; PMCID: PMC7088456.
  11. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, Anggrahini DW. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord. 2020 Apr 7;20(1):163. doi: 10.1186/s12872-020-01434-z. PMID: 32264836; PMCID: PMC7137468.
  12. Akagi S, Kasahara S, Akagi T, Ejiri K, Mitsuhashi T, Nakagawa K, Nakamura K, Ito H. Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension. JACC Adv. 2024 Mar 6;3(4):100887. doi: 10.1016/j.jacadv.2024.100887. PMID: 38939653; PMCID: PMC11198275.
  13. Ivy DD, Frank BS. Treat and Repair for Congenital Heart Disease and Pulmonary Hypertension: Not a Panacea. JACC Adv. 2024 Mar 11;3(4):100891. doi: 10.1016/j.jacadv.2024.100891. PMID: 38939683; PMCID: PMC11198098.
  14. Yan K, Gao LN, Cui YL, Zhang Y, Zhou X. The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review). Mol Med Rep. 2016 May;13(5):3715-23. doi: 10.3892/mmr.2016.5005. Epub 2016 Mar 18. PMID: 27035868; PMCID: PMC4838136.
  15. Martinsen A, Dessy C, Morel N. Regulation of calcium channels in smooth muscle: new insights into the role of myosin light chain kinase. Channels (Austin). 2014;8(5):402-13. doi: 10.4161/19336950.2014.950537. PMID: 25483583; PMCID: PMC4594426.
  16. Wu Y, Liu HM, Gu L, Li QW, Zhu L. Prostacyclins and pulmonary arterial hypertension in children. Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):37-45. doi: 10.26355/eurrev_202201_27745. PMID: 35049017.
  17. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr;4(4):291-305. doi: 10.1016/S2213-2600(16)00027-8. Epub 2016 Feb 27. Erratum in: Lancet Respir Med. 2016 Jun;4(6):e34. doi: 10.1016/S2213-2600(16)30091-1. PMID: 26935844.
  18. Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1095-1102. Epub 2018 Jun 14. PMID: 29998831.
  19. Liu HL, Chen XY, Li JR, Su SW, Ding T, Shi CX, Jiang YF, Zhu ZN. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. Chest. 2016 Aug;150(2):353-66. doi: 10.1016/j.chest.2016.03.031. Epub 2016 Apr 2. PMID: 27048870.
  20. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K; ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11;42(6):563-645. doi: 10.1093/eurheartj/ehaa554. PMID: 32860028.
  21. Egidy Assenza G, Krieger EV, Baumgartner H, Cupido B, Dimopoulos K, Louis C, Lubert AM, Stout KK, Valente AM, Zeppenfeld K, Opotowsky AR. AHA/ACC vs ESC Guidelines for Management of Adults With Congenital Heart Disease: JACC Guideline Comparison. J Am Coll Cardiol. 2021 Nov 9;78(19):1904-1918. doi: 10.1016/j.jacc.2021.09.010. PMID: 34736567.
  22. Gerardin JF, Menk JS, Pyles LA, Martin CM, Lohr JL. Compliance with Adult Congenital Heart Disease Guidelines: Are We Following the Recommendations? Congenit Heart Dis. 2016 May;11(3):245-53. doi: 10.1111/chd.12309. Epub 2015 Nov 11. PMID: 26554543.

Download Article
Received April 15, 2025.
Accepted June 1, 2025.
©2025 International Medical Research and Development Corporation.